Trader: Low Volume ...
Health Care: Drugs
A.P. Pharma Inc. (APPA: OTC)
$0.58 0.00 | 0.00%
06/04/12 - 10:32 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 646.00K | 1.30M | 1.26M | 369.00K |
| Cost of Sales | -282.00K | -227.00K | -356.00K | -412.00K |
| Gross Operating Profit | 928.00K | 1.53M | 1.62M | 781.00K |
| Selling, General, and Administrative Expenses | 3.50M | 3.97M | 3.71M | 4.31M |
| Research & Development | 8.21M | 7.26M | 7.80M | 19.51M |
| Operating Income before D & A (EBITDA) | -10.78M | -9.71M | -9.89M | -23.03M |
| Depreciation & Amortization | 282.00K | 227.00K | 356.00K | 412.00K |
| Interest Income | 0.00 | 0.00 | 29.00K | 587.00K |
| Other Income - Net | 0.00 | 2.74M | -127.00K | -67.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -11.06M | -7.19M | -10.34M | -22.92M |
| Interest Expense | 373.00K | 2.00K | 0.00 | 0.00 |
| Pre-Tax Income | -11.44M | -7.20M | -10.34M | -22.92M |
| Income Taxes | 0.00 | 0.00 | -122.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -11.44M | -7.20M | -10.22M | -22.92M |
| Net Income From Discontinued Operations | -379.00K | -150.00K | 0.00 | 0.00 |
| Net Income From Total Operations | -11.81M | -7.35M | -10.22M | -22.92M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 190.00K | -200.00K |
| Total Net Income | -11.81M | -7.35M | -10.03M | -23.12M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-11.44M | -7.20M | -10.22M | -22.92M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -11.44M | -7.20M | -10.22M | -22.92M |
| Basic EPS from Continuing Ops. | -0.10 | -0.18 | -0.31 | -0.74 |
| Basic EPS from Discontinued Ops. | 0.00 | -0.01 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.10 | -0.19 | -0.31 | -0.74 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | -0.01 |
| Basic EPS, Total | -0.10 | -0.19 | -0.31 | -0.75 |
| Basic Normalized Net Income/Share | -0.10 | -0.18 | -0.31 | -0.74 |
| EPS fr Continuing Ops. | -0.10 | -0.18 | -0.31 | -0.74 |
| EPS fr Discontinued Ops | 0.00 | -0.01 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.10 | -0.19 | -0.31 | -0.74 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS, Total | -0.10 | -0.19 | -0.31 | -0.75 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.10 | -0.18 | -0.31 | -0.74 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with APPA
- Portfolio NameUser Type
- UserMy Folio
- Userwatchlist1
- UserMARK 1 C
- ContributorBarron's Insider Purchases ...
- UserSUPRATRADE-2709091838
- UserLatest Activist Filings 2-2...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- UserBarron's Insider Purchases ...
Latest APPA Headlines from TheStreet
- Ambac Financial, QAD: Early Volume Plays 05.18.10 | 08:05 am
- A.P. Pharma, Netlist: Early Volume Plays 03.19.10 | 10:03 am
- Biotech Stock Mailbag: Sequenom 03.12.10 | 07:03 am
- Latest News in Activist Investing 02.26.09 | 11:02 am
- Insider Action: Trading Level 3 10.03.08 | 12:10 pm
- Monday's Small-Cap Winners & Losers 06.25.07 | 04:06 pm
- Thursday's Health Winners & Losers 12.21.06 | 01:12 pm
- Monday's Small-Cap Winners & Losers 10.02.06 | 03:10 pm
Press Releases for APPA
- A.P. Pharma Announces Study Finding Continuous Exposure To A 5-HT3 Antagonist Using APF530 Provides Better Emetic Control - Business Wire 05.31.12 | 08:05 am
- A.P. Pharma Announces First Quarter 2012 Financial Results And Recent Corporate Progress - Business Wire 05.10.12 | 08:05 am
- A.P. Pharma Announces Third Quarter 2011 Financial Results And Recent Corporate Progress - Business Wire 11.07.11 | 08:11 am
- LifeSci Advisors Announces Investment Opinion On A.P. Pharma Inc. - Business Wire 08.29.11 | 01:08 pm
- A.P. Pharma Announces Second Quarter 2011 Financial Results And Reports On Recent Corporate Progress - Business Wire 08.08.11 | 08:08 am
- A.P. Pharma To Raise $24 Million In Private Placement Of Common Stock And Warrants - Business Wire 06.29.11 | 08:06 am
- A.P. Pharma Announces First Quarter 2011 Financial Results And Recent Corporate Progress - Business Wire 05.16.11 | 08:05 am
- A.P. Pharma Announces Financing Of Up To $4.5 Million And Names CEO And COO - Business Wire 04.25.11 | 08:04 am
- A.P. Pharma Provides Regulatory Update On APF530 NDA - Business Wire 04.25.11 | 08:04 am
- A.P. Pharma Announces Transfer To OTCQB - Business Wire 03.31.11 | 06:03 am
Partner Headlines for APPA
- Mannkind Slashes Staff: Biotech's Latest Tribulations - Seeking Alpha 02.13.11 | 08:02 am
- UPDATE 3-FDA denies approval of AP Pharma nausea drug; shrs sink - Reuters 03.19.10 | 12:03 pm
